Lenz Therapeutics News and Activities

Lenz Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Lenz Therapeutics is a company listed under the stock ticker LENZ (US).

View the org chart displaying its 16 main executives

Most searched biographies at Lenz Therapeutics

• Eef Schimmelpennink, President and Chief Executive Officer
• James Mccollum, Director
• Fred Guerard, Chairman of the Board

Popular executive movements at Lenz Therapeutics

• Zach Scheiner, Director, has left the company  (posted on July 3 2026).

Create your alert
to follow the executive moves at Lenz Therapeutics.

Lenz Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Lenz Therapeutics

• LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
• LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
• LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
• LENZ Therapeutics to Participate in Upcoming Investor Conferences
• Press Releases
• LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
• LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
• LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
• LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
• LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
• View more press releases Close

Social media about Lenz Therapeutics

• Lenz Therapeutics on Wikipedia, Google News & Yahoo Finance
• Lenz Therapeutics on LinkedIn, X (Twitter) & YouTube